Study to compare GW815SF [salmeterol/fluticasone-propionate] HFA MDI [hydrofluoroalkane metered-dose inhaler] with concomitant treatment with salmeterol xinafoate DPI [dry powder inhaler] plus fluticasone propionate DPI and to assess long-term safety of GW815SF HFA MDI.

Trial Profile

Study to compare GW815SF [salmeterol/fluticasone-propionate] HFA MDI [hydrofluoroalkane metered-dose inhaler] with concomitant treatment with salmeterol xinafoate DPI [dry powder inhaler] plus fluticasone propionate DPI and to assess long-term safety of GW815SF HFA MDI.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Aug 2016

At a glance

  • Drugs Salmeterol/fluticasone propionate (Primary) ; Fluticasone propionate; Salmeterol
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 18 Aug 2009 Actual patient number (51) added as reported by ClinicalTrials.gov.
    • 15 Oct 2008 Actual start date changed from Mar 2007 to Apr 2007 as reported by ClinicalTrials.gov.
    • 14 Jul 2008 The actual end date is now 1 Jan 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top